FDG-PET/CT in the Monitoring of Lymphoma Immunotherapy Response: Current Status and Future Prospects

FDG-PET/CT in the Monitoring of Lymphoma Immunotherapy Response: Current Status and Future Prospects

Cancer immunotherapy has been extensively investigated in lymphoma over the last three decades. This new treatment modality is now established as a way to manage and maintain several stages and subtypes of lymphoma. The establishment of this novel therapy has necessitated the development of new imag...

Full description

Bibliographic Details
Main Authors:	Akram Al-Ibraheem, Ahmed Saad Abdlkadir, Malik E. Juweid, Kamal Al-Rabi, Mohammad Ma’koseh, Hikmat Abdel-Razeq, Asem Mansour
Format:	Article
Language:	English
Published:	MDPI AG 2023-02-01
Series:	Cancers
Subjects:	immunotherapy 1 immunotherapy in lymphoma 2 FDG PET/CT 3 metabolic PET parameters 4 lymphoma immunotherapy response criteria 5 immuno-PET 6
Online Access:	https://www.mdpi.com/2072-6694/15/4/1063

Similar Items

Assessment of Response to Immunotherapy in Patients with Hodgkin Lymphoma: Towards Quantifying Changes in Tumor Burden Using FDG-PET/CT
by: Francesca Tutino, et al.
Published: (2023-05-01)

Early Evaluation of Immunotherapy Response in Lymphoma Patients by 18F-FDG PET/CT: A Literature Overview
by: Cristina Ferrari, et al.
Published: (2021-03-01)

PET/CT in Patients with Breast Cancer Treated with Immunotherapy
by: Sofia C. Vaz, et al.
Published: (2023-05-01)

FDG-PET/CT in Lymphoma: Where Do We Go Now?
by: Yassine Al Tabaa, et al.
Published: (2021-10-01)

Diagnostic performance of prospective same-day 18F-FDG PET/MRI and 18F-FDG PET/CT in the staging and response assessment of lymphoma
by: Vijay Mistry, et al.
Published: (2023-01-01)

FDG-PET in mantle cell lymphoma involving skin
by: Mehmet Sönmez, et al.
Published: (2010-12-01)

Impact of [<sup>18</sup>F]FDG PET/CT in the Assessment of Immunotherapy-Induced Arterial Wall Inflammation in Melanoma Patients Receiving Immune Checkpoint Inhibitors
by: Shaghayegh Ranjbar, et al.
Published: (2023-05-01)

Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [<sup>18</sup>F]FDG PET/CT in Metastatic Melanomas and Lung Cancer
by: Egesta Lopci
Published: (2021-11-01)

Adapting Imaging Protocols for PET-CT and PET-MRI for Immunotherapy Monitoring
by: Bettina Beuthien-Baumann, et al.
Published: (2021-11-01)

[18F]FDG-PET/CT Radiomics for Prediction of Bone Marrow Involvement in Mantle Cell Lymphoma: A Retrospective Study in 97 Patients
by: Marius E. Mayerhoefer, et al.
Published: (2020-05-01)

Neurolymphomatosis: Unusual Extranodal Involvement Pattern on 18F-FDG PET/CT in a Non-Hodgkin Lymphoma Recurrence
by: Marcos Pretto Mosmann, et al.
Published: (2011-04-01)

FDG‐PET/CT‐guided rebiopsy may find clinically unsuspicious transformation of follicular lymphoma
by: Aino Rajamäki, et al.
Published: (2023-01-01)

Concomitant Prostate Cancer and Hodgkin Lymphoma: A Differential Diagnosis Guided by a Combined 68Ga-PSMA-11 and 18F-FDG PET/CT Approach
by: Alberto Miceli, et al.
Published: (2021-09-01)

[<sup>18</sup>F]FDG PET/CT in the Evaluation of Melanoma Patients Treated with Immunotherapy
by: María Mangas Losada, et al.
Published: (2023-03-01)

Prognostic value and clinical impact of 18FDG-PET in the management of children with Burkitt lymphoma after induction chemotherapy.
by: clement eBailly, et al.
Published: (2014-12-01)

Brain Metastases Unresponsive to Immunotherapy Detected by 18F-FDG-PET/CT in a Patient with Melanoma
by: Rosa Fonti, et al.
Published: (2020-06-01)

[18F]FDG PET/CT and PET/MR in Patients with Adrenal Lymphoma: A Systematic Review of Literature and a Collection of Cases
by: Laura Evangelista, et al.
Published: (2022-10-01)

Prognostic Value of FDG PET/CT in Patients with Nodal Peripheral T-Cell Lymphoma
by: Woo Hee Choi, et al.
Published: (2023-09-01)

Clinical value of 18F-FDG PET/CT in the management of HIV-associated lymphoma
by: Qi Liu, et al.
Published: (2023-01-01)

Response to Immune Checkpoint Inhibitor Therapy in Patients with Unresectable Recurrent Malignant Pleural Mesothelioma Shown by FDG-PET and CT
by: Kazuhiro Kitajima, et al.
Published: (2021-03-01)

Gallbladder Involvement of Diffuse Large B-Cell Lymphoma with 18F-FDG PET/CT
by: Esra Arslan, et al.
Published: (2022-05-01)

FDG-PET Response Prediction in Pediatric Hodgkin’s Lymphoma: Impact of Metabolically Defined Tumor Volumes and Individualized SUV Measurements on the Positive Predictive Value
by: Amr Elsayed M. Hussien, et al.
Published: (2015-01-01)

Comparison of FDG PET/CT and Bone Marrow Biopsy Results in Patients with Diffuse Large B Cell Lymphoma with Subgroup Analysis of PET Radiomics
by: Eun Ji Han, et al.
Published: (2022-01-01)

FDG-PET/CT for the Management of Post-Chemotherapy Residual Mass in Hodgkin lymphoma
by: Andrea Gallamini, et al.
Published: (2021-08-01)

Longitudinal Body Composition Changes Detected by [<sup>18</sup>F]FDG PET/CT during and after Chemotherapy and Their Prognostic Role in Elderly Hodgkin Lymphoma
by: Domenico Albano, et al.
Published: (2022-10-01)

Unmasking Coincident Hodgkin Lymphoma and Giant Cell Tumor: Insights from [18F] FDG PET/CT
by: Akram Al-ibraheem, et al.
Published: (2024-01-01)

Characterization of Mediastinal Bulky Lymphomas with FDG-PET-Based Radiomics and Machine Learning Techniques
by: Elisabetta Maria Abenavoli, et al.
Published: (2023-03-01)

ITA-IMMUNO-PET: The Role of [18F]FDG PET/CT for Assessing Response to Immunotherapy in Patients with Some Solid Tumors
by: Laura Evangelista, et al.
Published: (2023-01-01)

Concomitant thyroiditis and orchitis induced by immune checkpoint inhibitors detected on [18F]FDG PET/CT
by: Luca Filippi, et al.
Published: (2024-03-01)

Follicular lymphoma presenting as a seminal vesicle mass: Diagnostic path from prostate MRI to 18F-FDG PET/CT
by: Burcin Agridag Ucpinar, MD, et al.
Published: (2023-08-01)

18FDG PET Assessment of Therapeutic Response in Patients with Advanced or Metastatic Melanoma Treated with First-Line Immune Checkpoint Inhibitors
by: Alexia Rivas, et al.
Published: (2022-06-01)

Potentials of Non-Invasive 18F-FDG PET/CT in Immunotherapy Prediction for Non–Small Cell Lung Cancer
by: Xuhe Liao, et al.
Published: (2022-02-01)

Comparison of 18F-FDG PET/CT and conventional methods in diagnosing extranodal natural killer/T-cell lymphoma
by: Huixia Geng, et al.
Published: (2024-01-01)

Blood‐circulating EV‐miRNAs, serum TARC, and quantitative FDG‐PET features in classical Hodgkin lymphoma
by: Esther E. E. Drees, et al.
Published: (2022-08-01)

Immuno-Imaging (PET/SPECT)–Quo Vadis?
by: Carsten S. Kramer, et al.
Published: (2022-05-01)

The Prognostic and Diagnostic Value of [<sup>18</sup>F]FDG PET/CT in Untreated Laryngeal Carcinoma
by: Akram Al-Ibraheem, et al.
Published: (2023-05-01)

Prediction of prognosis and pathologic grade in follicular lymphoma using 18F-FDG PET/CT
by: Hongyan Li, et al.
Published: (2022-07-01)

The role of 18F-FDG PET/CT in the management of large-vessel vasculitis: applications and limitations in clinical practice
by: Maria V. Mattoli, et al.
Published: (2012-01-01)

The prognostic value of pretreatment 18F-FDG PET/CT in extranodal natural killer/T-cell lymphoma
by: FENG Guowei, ZHANG Xiaojuan, GUO Rui, GUAN Zhe, WANG Yue
Published: (2021-12-01)

Hypermetabolic abdominal and cervical lymph nodes mimicking Hodgkin lymphoma relapse on FDG PET/CT after adenovirus-vectored COVID-19 vaccine
by: Elena Landete, et al.
Published: (2021-12-01)